Welcome Back
Click “Sign in” to agree to Cointime’s Terms of Service and acknowledge that Cointime’s Privacy Policy applies to you.
Join CoinTime
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">Terms of Service</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">Privacy Policy</a> applies to you.
Sign in with email
Sign up with email
Your email
Check your inbox
Click the link we sent to to sign in.
Click the link we sent to to sign up.
CEJ Capital
investment firm
About
CEJ Capital is a venture capital arm of CYBERDYNE.
- Tsukuba,Ibaraki,Japan
Highlights
Details
- Industries
- Finance,Financial Services,Venture Capital
- Founded date
- Jan 1, 2017
- Operating Status
- Active
- Legal Name
- CEJ Capital Co., Ltd.
- Also Known As
- CEJキャピタル
- Investor Type
- CVC
CEJ Capital is a venture capital arm of CYBERDYNE. It engages in the creation of cybernics industry, management, and management of growth promotion investment business association property.
Funds Raised
| Announced Date | Fund Name | Money Raised | |
|---|---|---|---|
| Jul 12, 2018 | Cybernics Excellence Japan Fund I | ¥9.20B |
Investments
Number of Investments
Number of Lead Investments
8
1
CEJ Capital has made 8 investments. Their most recent investment was on
Sep 21, 2021, when GAIA BioMedicine raised ¥1.30B.
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Sep 21, 2021
GAIA BioMedicine
|
Series B | ¥1.30B | Compliance | — |
|
Mar 23, 2021
Jiksak Bioengineering
|
Series B | — | Biometrics | Yes |
|
Sep 7, 2020
ANSeen
|
Series B | ¥0.90B | Industrial Manufacturing | — |
|
Apr 20, 2020
AMI Japan
|
Series Unknown | ¥490M | Health Care | — |
|
Feb 28, 2020
Kringle Pharma
|
Series Unknown | ¥0.95B | Biotechnology | — |
Exits
CEJ Capital has had 1 exits. CEJ Capital most notable exits include Kringle Pharma
| Date | Company Name | Exit Type | Industry | |
|---|---|---|---|---|
| Dec 28, 2020 | Kringle Pharma | IPO | Biotechnology | Detail |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
